Short Interest in BioAtla, Inc. (NASDAQ:BCAB) Rises By 32.7%

BioAtla, Inc. (NASDAQ:BCAB) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 4,220,000 shares, an increase of 32.7% from the February 28th total of 3,180,000 shares. Currently, 9.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is currently 4.0 days.

BioAtla Trading Up 1.8 %

Shares of BCAB stock opened at $0.35 on Wednesday. BioAtla has a twelve month low of $0.24 and a twelve month high of $4.02. The company’s 50-day moving average price is $0.40 and its 200-day moving average price is $1.10. The stock has a market cap of $17.08 million, a price-to-earnings ratio of -0.21 and a beta of 1.19.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. As a group, equities research analysts predict that BioAtla will post -1.46 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of BioAtla in a research report on Monday.

Hedge Funds Weigh In On BioAtla

Several hedge funds and other institutional investors have recently made changes to their positions in BCAB. Magnus Financial Group LLC purchased a new stake in shares of BioAtla in the 4th quarter valued at about $28,000. Two Sigma Investments LP increased its holdings in shares of BioAtla by 84.0% in the 4th quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after acquiring an additional 61,725 shares during the period. Jane Street Group LLC raised its holdings in shares of BioAtla by 204.1% in the fourth quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after buying an additional 100,204 shares during the last quarter. Norges Bank purchased a new position in shares of BioAtla during the fourth quarter worth about $230,000. Finally, XTX Topco Ltd increased its position in BioAtla by 7.2% in the 3rd quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after acquiring an additional 10,384 shares during the period. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.